BioCentury
ARTICLE | Company News

Amsterdam Molecular discontinues Glybera

October 26, 2011 12:39 AM UTC

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) discontinued development of Glybera following last week's second CHMP decision against approval of the product in the EU for lipoprotein lipase (LPL) deficiency. The company will also reduce headcount by 50% to 45 and discontinue development of AMT-080, which was in preclinical testing for Duchenne muscular dystrophy (DMD). Amsterdam Molecular expects the changes to reduce its burn rate to EUR 500,000-EUR 600,000 ($694,000-$833,000) per month from EUR 1.5 million ($2.1 million) per month. Glybera is an AAV vector encoding the LPL gene (see BioCentury Extra, Oct. 21). ...